Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P51532 (
transcriptional activator
)
6,546
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
SETD7
is a methyltransferase that specifically catalyzes the monomethylation of lysine 4 on histone H3. A variety of studies has revealed the role of
SETD7
in posttranslational modifications of non-histone proteins. However, the prognostic value of
SETD7
on breast cancer and the ability of
SETD7
of regulating intrinsic redox homeostasis has never been investigated. In this study, using The Cancer Genome Atlas (TCGA) database, we revealed that
SETD7
was a potential prognostic marker of breast cancer. Median survival time of patients with low
SETD7
expression (18.1 years) was twice than that of
SETD7
low-expressed patients (9.5 years). We demonstrated that
SETD7
promoted tumor cell proliferation and prevented cell apoptosis and that
SETD7
delicately maintained the redox homeostasis through regulating the levels of GSH/GSSG and ROS. Further studies indicated that
SETD7
was a positive activator of KEAP1-NRF2 pathway. Using dual luciferase assay, we revealed the role of
SETD7
as a
transcriptional activator
of antioxidant enzymes. Downregulation of
SETD7
in MCF7 and MDA-MB-231 cells impaired the expression of antioxidant enzymes and induces imbalance of redox status. Together, we proposed
SETD7
as a prognostic marker of breast cancer and a novel antioxidant promoter under oxidative stress in breast cancer.
...
PMID:SETD7 is a prognosis predicting factor of breast cancer and regulates redox homeostasis. 2921 11
